Search alternatives:
significant hits » significant units (Expand Search), significant bias (Expand Search), significant anti (Expand Search)
gap increases » rapid increases (Expand Search), shape increases (Expand Search), _ increases (Expand Search)
hits decrease » sizes decrease (Expand Search), visits decreased (Expand Search)
Showing 161 - 180 results of 5,209 for search '(( significant gap increases ) OR ( significant hits decrease ))', query time: 1.01s Refine Results
  1. 161
    Co dopant Concentration vs. average crystallite size.

    Co dopant Concentration vs. average crystallite size. by Adil Muhammad (13003230)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  2. 162
    Shows the percentage of Zn, O and Co different samples.

    Shows the percentage of Zn, O and Co different samples. by Adil Muhammad (13003230)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  3. 163
    Increase in student knowledge and skills after genomics CURE.

    Increase in student knowledge and skills after genomics CURE. by Seema B. Plaisier (14892009)

    Published 2024
    Save to List
    Saved in:
  4. 164
    Current health gap scorecard: American countries.

    Current health gap scorecard: American countries. by Fabrício Silveira (12902492)

    Published 2022
    “…<p>Notes: Indicators 3.b.1a,b,c and 17.19.2 omitted due to the lack of statistical significance of the estimations. The gap index was adjusted to indicate improvement upwards and worsening downwards regardless of the direction of improvement of the indicator. …”
    Save to List
    Saved in:
  5. 165
    Diagram of confirmatory model: Regression coefficients for all significant paths at p < 0.001 level (n = 1637).

    Diagram of confirmatory model: Regression coefficients for all significant paths at p < 0.001 level (n = 1637). by Jing Zhou (168494)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 166
    Syndecan-3 ectodomain increases vascular leakage in mouse lung.

    Syndecan-3 ectodomain increases vascular leakage in mouse lung. by Melanie Jannaway (6703577)

    Published 2019
    Save to List
    Saved in:
  7. 167
    Speech perception vs. CAEP amplitude and latency scatter plots.

    Speech perception vs. CAEP amplitude and latency scatter plots. by Chelsea M. Blankenship (13955307)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  8. 168
    NH and CI group mean across-frequency CAEP waveforms.

    NH and CI group mean across-frequency CAEP waveforms. by Chelsea M. Blankenship (13955307)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  9. 169
    NH and CI group mean within-frequency CAEP amplitude and latency values.

    NH and CI group mean within-frequency CAEP amplitude and latency values. by Chelsea M. Blankenship (13955307)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  10. 170
    Cochlear implant recipient demographic and device information.

    Cochlear implant recipient demographic and device information. by Chelsea M. Blankenship (13955307)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  11. 171
    NH and CI group mean within-frequency CAEP waveforms.

    NH and CI group mean within-frequency CAEP waveforms. by Chelsea M. Blankenship (13955307)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  12. 172
    NH and CI group mean audiometric thresholds.

    NH and CI group mean audiometric thresholds. by Chelsea M. Blankenship (13955307)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  13. 173
    NH and CI group mean across-frequency CAEP amplitude and latency values.

    NH and CI group mean across-frequency CAEP amplitude and latency values. by Chelsea M. Blankenship (13955307)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  14. 174
    Within- and across-frequency stimuli.

    Within- and across-frequency stimuli. by Chelsea M. Blankenship (13955307)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  15. 175
    The trend of observed changes in t<sub>balance</sub>, t<sub>peak</sub> and D<sub>max</sub>, with increasing IOP levels.

    The trend of observed changes in t<sub>balance</sub>, t<sub>peak</sub> and D<sub>max</sub>, with increasing IOP levels. by Ali Dahaghin (14294321)

    Published 2025
    Save to List
    Saved in:
  16. 176
    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for Parkinson’s Disease

    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for... by Javier García-Cárceles (2073898)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  17. 177
    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for Parkinson’s Disease

    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for... by Javier García-Cárceles (2073898)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  18. 178
    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for Parkinson’s Disease

    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for... by Javier García-Cárceles (2073898)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  19. 179
    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for Parkinson’s Disease

    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for... by Javier García-Cárceles (2073898)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  20. 180
    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for Parkinson’s Disease

    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for... by Javier García-Cárceles (2073898)

    Published 2022
    Subjects:
    Save to List
    Saved in:

Search Tools: